Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
Claudia Campani, Jessica Zucman‐Rossi, Jean–Charles Nault
Cancers (2023) Vol. 15, Iss. 3, pp. 817-817
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Development and evaluation of hyaluronic acid-coated chitosan nanoparticles for improved delivery of sorafenib tosylate in the treatment of hepatocellular carcinoma
Putrevu Sreelaya, Sankha Bhattacharya, Darshan Bhirud, et al.
BioNanoScience (2025) Vol. 15, Iss. 1
Closed Access | Times Cited: 2
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis
Baofa Yu, Wenxue Ma
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 29-38
Closed Access | Times Cited: 12
Circulating tumor DNA and its role in detection, prognosis and therapeutics of hepatocellular carcinoma
Sana Rashid, Yingchuan Sun, Umair Ali Khan Saddozai, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 2, pp. 195-214
Open Access | Times Cited: 10
The therapeutic role of naringenin nanoparticles on hepatocellular carcinoma
Ayman Mahmoud Elwan, Tarek M. Mohamed, Doha M. Beltagy, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc
Latifa Bakiri, Sebastian C. Hasenfuss, Ana Guío-Carrión, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 18
Closed Access | Times Cited: 8
The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications
Konstantinos Arvanitakis, Ioannis Mitroulis, Antonios Chatzigeorgiou, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1522-1522
Open Access | Times Cited: 14
Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation
Panagiota Maravelia, Hongyang Yao, Curtis Cai, et al.
Gut (2025), pp. gutjnl-334148
Closed Access
MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model
Wiktoria Bębenek, Arkadiusz Gajek, Agnieszka Marczak, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 834-834
Open Access
Somatic Copy Number Alterations in Circulating Cell-Free DNA as a Prognostic Biomarker for Hepatocellular Carcinoma: Insights from a Proof-of-Concept Study
Elisa Pinto, Elisabetta Lazzarini, Filippo Pelizzaro, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1115-1115
Open Access
A Super-Assembled Synergistically Nanoplatform AP@ZIF-8Pt for Hepatocarcinoma Therapy
Zhenzhen Luo, Dunhuang Wang, Lie Lin, et al.
International Journal of Nanomedicine (2025) Vol. Volume 20, pp. 5681-5692
Open Access
Insights into Sorafenib resistance in hepatocellular carcinoma: Mechanisms and therapeutic aspects.
Eman H. Yousef, Amal M. El Gayar, Nada F. Abo El‐Magd
Critical Reviews in Oncology/Hematology (2025), pp. 104765-104765
Closed Access
Upfront multi‐bipolar radiofrequency ablation for HCC in transplant‐eligible cirrhotic patients with salvage transplantation in case of recurrence
Carina Boros, Olivier Sutter, François Cauchy, et al.
Liver International (2024) Vol. 44, Iss. 6, pp. 1464-1473
Closed Access | Times Cited: 3
Unleashing the potential of gene signatures as prognostic and predictive tools: A step closer to personalized medicine in hepatocellular carcinoma (HCC)
Atieh Pourbagheri‐Sigaroodi, Fatemeh Fallah, Davood Bashash, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 2
The Role of HSP90 and TRAP1 Targets on Treatment in Hepatocellular Carcinoma
Praveen Kumar, Harini Sundar, K Balakrishnan, et al.
Molecular Biotechnology (2024)
Closed Access | Times Cited: 2
Metadherin-driven promotion of cancer stem cell phenotypes and its effect on immunity in hepatocellular carcinoma
Nevena Todorović, Amedeo Amedei
World Journal of Gastroenterology (2024) Vol. 30, Iss. 20, pp. 2624-2628
Open Access | Times Cited: 2
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
The p53 Family of Transcription Factors Represses the Alpha- fetoprotein Gene Expression in Hepatocellular Carcinoma
Gisela Wölfel, Elisabeth Ostheim, Agnes Staub, et al.
Journal of Gastrointestinal and Liver Diseases (2023) Vol. 32, Iss. 3, pp. 346-355
Open Access | Times Cited: 4
Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc (Author copy)
Latifa Bakiri
Authorea (Authorea) (2024)
Open Access | Times Cited: 1
Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma
Min Yao, Rong-Fei Fang, Qun Xie, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 16, Iss. 6, pp. 2350-2361
Open Access | Times Cited: 1
Mechanistic Insights and Therapeutic Applications of Hinokitiol in Inflammation, Antimicrobial Therapy, and Cancer
Karthik K Karunakar, Binoy Varghese Cheriyan, Ramaiyan Velmurugan, et al.
Pharmacological Research - Modern Chinese Medicine (2024) Vol. 13, pp. 100527-100527
Open Access | Times Cited: 1
Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development
Nevena Todorović, Serena Martinelli, Giulia Nannini, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13510-13510
Open Access | Times Cited: 1
Benefit and harm of waiting time in liver transplantation for HCC
Pam Elisabeth van der Meeren, Roeland F. de Wilde, Dave Sprengers, et al.
Hepatology (2023)
Closed Access | Times Cited: 2
Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology
Afzal Ansari, Suman Kumar Ray, Mukul Sharma, et al.
Current Molecular Medicine (2023) Vol. 24, Iss. 12, pp. 1461-1469
Closed Access | Times Cited: 2
[TRIM21 Inhibits the Proliferation and Migration of Lung Adenocarcinoma Cells 
by Interacting with ZSWIM1].
Luxuan Chen, Qionghua Lian, Gui Zhang, et al.
PubMed (2024) Vol. 27, Iss. 5, pp. 337-344
Closed Access
Comprehensive Management of Hepatocellular Carcinoma: A Review of Current Surgical, Locoregional, and Systemic Therapies
Omnia Ahmed, Rehab H. Werida, Safaa Askar, et al.
Deleted Journal (2024)
Open Access
Page 1 - Next Page

Scroll to top